145 related articles for article (PubMed ID: 12549728)
1. Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?
Shen B; Soffer EE
Cleve Clin J Med; 2003 Jan; 70(1):64-5. PubMed ID: 12549728
[No Abstract] [Full Text] [Related]
2. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
McGahan L
Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
[No Abstract] [Full Text] [Related]
3. Alosetron for irritable bowel syndrome.
Lièvre M
BMJ; 2002 Sep; 325(7364):555-6. PubMed ID: 12228116
[No Abstract] [Full Text] [Related]
4. Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.
Palmer JB
BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12511473
[No Abstract] [Full Text] [Related]
5. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
6. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
7. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
[TBL] [Abstract][Full Text] [Related]
8. FDA draws patients into alosetron risk management.
Miller JL
Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021
[No Abstract] [Full Text] [Related]
9. FDA advisory panels recommend Lotronex be put back on market.
Charatan F
BMJ; 2002 May; 324(7345):1053. PubMed ID: 11993482
[No Abstract] [Full Text] [Related]
10. Contemporary thoughts on the treatment of irritable bowel syndrome.
Giaquinta D
Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060
[No Abstract] [Full Text] [Related]
11. New drugs to treat irritable bowel syndrome being tested.
Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
[No Abstract] [Full Text] [Related]
12. Pharmacogenomics and functional gastrointestinal disorders.
Camilleri M
Pharmacogenomics; 2005 Jul; 6(5):491-501. PubMed ID: 16013999
[TBL] [Abstract][Full Text] [Related]
13. Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.
Whorwell PJ
Gut; 2001 May; 48(5):596-7. PubMed ID: 11302953
[No Abstract] [Full Text] [Related]
14. So what happened to alosetron?
Hyams JS
J Pediatr Gastroenterol Nutr; 2001 May; 32(5):513-4. PubMed ID: 11455947
[No Abstract] [Full Text] [Related]
15. Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
Palmer RH
BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12518769
[No Abstract] [Full Text] [Related]
16. Novel medications for the irritable bowel syndrome: motility and sensation.
Camilleri M
J Pediatr Gastroenterol Nutr; 2001; 32 Suppl 1():S35-7. PubMed ID: 11321419
[No Abstract] [Full Text] [Related]
17. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
18. Review article: clinical pharmacology of alosetron.
Gunput MD
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
[TBL] [Abstract][Full Text] [Related]
19. Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.
Olden KW
Cleve Clin J Med; 2003 Jun; 70 Suppl 2():S3-7. PubMed ID: 12825862
[No Abstract] [Full Text] [Related]
20. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
